Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

BTSG vs DBVT vs ALKS vs LFST

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
BTSG
BrightSpring Health Services, Inc. Common Stock

Medical - Healthcare Information Services

HealthcareNASDAQ • US
Market Cap$10.23B
5Y Perf.+380.4%
DBVT
DBV Technologies S.A.

Biotechnology

HealthcareNASDAQ • FR
Market Cap$1712.35T
5Y Perf.+118.5%
ALKS
Alkermes plc

Biotechnology

HealthcareNASDAQ • IE
Market Cap$5.90B
5Y Perf.+30.9%
LFST
LifeStance Health Group, Inc.

Medical - Care Facilities

HealthcareNASDAQ • US
Market Cap$3.43B
5Y Perf.+48.0%

BTSG vs DBVT vs ALKS vs LFST — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
BTSG logoBTSG
DBVT logoDBVT
ALKS logoALKS
LFST logoLFST
IndustryMedical - Healthcare Information ServicesBiotechnologyBiotechnologyMedical - Care Facilities
Market Cap$10.23B$1712.35T$5.90B$3.43B
Revenue (TTM)$13.65B$0.00$1.56B$1.49B
Net Income (TTM)$310M$-168M$153M$23M
Gross Margin12.2%65.4%21.7%
Operating Margin3.3%12.3%3.0%
Forward P/E34.0x24.8x121.1x
Total Debt$2.84B$22M$70M$194M
Cash & Equiv.$88M$194M$1.12B$249M

BTSG vs DBVT vs ALKS vs LFSTLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

BTSG
DBVT
ALKS
LFST
StockJan 24May 26Return
BrightSpring Health… (BTSG)100480.4+380.4%
DBV Technologies S.… (DBVT)100218.5+118.5%
Alkermes plc (ALKS)100130.9+30.9%
LifeStance Health G… (LFST)100148.0+48.0%

Price return only. Dividends and distributions are not included.

Quick Verdict: BTSG vs DBVT vs ALKS vs LFST

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: ALKS leads in 4 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. BrightSpring Health Services, Inc. Common Stock is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
BTSG
BrightSpring Health Services, Inc. Common Stock
The Growth Play

BTSG is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.

  • Rev growth 14.6%, EPS growth 10.3%, 3Y rev CAGR 18.7%
  • 381.3% 10Y total return vs ALKS's -11.0%
  • 14.6% revenue growth vs DBVT's -100.0%
  • +129.8% vs ALKS's +16.5%
Best for: growth exposure and long-term compounding
DBVT
DBV Technologies S.A.
The Income Pick

DBVT is the clearest fit if your priority is income & stability.

  • Dividend streak 0 yrs, beta 1.26
Best for: income & stability
ALKS
Alkermes plc
The Defensive Pick

ALKS carries the broadest edge in this set and is the clearest fit for sleep-well-at-night and defensive.

  • Lower volatility, beta 1.06, Low D/E 3.8%, current ratio 3.55x
  • Beta 1.06, current ratio 3.55x
  • Lower P/E (24.8x vs 121.1x)
  • 9.8% margin vs DBVT's 0.3%
Best for: sleep-well-at-night and defensive
LFST
LifeStance Health Group, Inc.
The Quality Angle

LFST lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
See the full category breakdown
CategoryWinnerWhy
GrowthBTSG logoBTSG14.6% revenue growth vs DBVT's -100.0%
ValueALKS logoALKSLower P/E (24.8x vs 121.1x)
Quality / MarginsALKS logoALKS9.8% margin vs DBVT's 0.3%
Stability / SafetyALKS logoALKSBeta 1.06 vs BTSG's 1.46, lower leverage
DividendsTieNone of these 4 stocks pay a meaningful dividend
Momentum (1Y)BTSG logoBTSG+129.8% vs ALKS's +16.5%
Efficiency (ROA)ALKS logoALKS5.4% ROA vs DBVT's -89.0%

BTSG vs DBVT vs ALKS vs LFST — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

BTSGBrightSpring Health Services, Inc. Common Stock
FY 2025
Commercial Insurance
68.8%$3.3B
Medicaid
31.2%$1.5B
DBVTDBV Technologies S.A.

Segment breakdown not available.

ALKSAlkermes plc
FY 2025
Vivitrol
39.8%$468M
Aristada And Aristada Initio
31.5%$370M
Manufactured Product And Royalty
24.8%$291M
Manufacturing Revenue
3.9%$46M
LFSTLifeStance Health Group, Inc.

Segment breakdown not available.

BTSG vs DBVT vs ALKS vs LFST — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLALKSLAGGINGLFST

Income & Cash Flow (Last 12 Months)

ALKS leads this category, winning 5 of 6 comparable metrics.

BTSG and DBVT operate at a comparable scale, with $13.6B and $0 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to LFST's 1.6%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricBTSG logoBTSGBrightSpring Heal…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcLFST logoLFSTLifeStance Health…
RevenueTrailing 12 months$13.6B$0$1.6B$1.5B
EBITDAEarnings before interest/tax$572M-$112M$212M$100M
Net IncomeAfter-tax profit$310M-$168M$153M$23M
Free Cash FlowCash after capex$508M-$151M$392M$179M
Gross MarginGross profit ÷ Revenue+12.2%+65.4%+21.7%
Operating MarginEBIT ÷ Revenue+3.3%+12.3%+3.0%
Net MarginNet income ÷ Revenue+2.3%+9.8%+1.6%
FCF MarginFCF ÷ Revenue+3.7%+25.1%+12.0%
Rev. Growth (YoY)Latest quarter vs prior year+25.6%+28.2%+21.2%
EPS Growth (YoY)Latest quarter vs prior year+142.9%+91.5%-4.1%
ALKS leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

Evenly matched — BTSG and DBVT and ALKS each lead in 2 of 6 comparable metrics.

At 24.8x trailing earnings, ALKS trades at a 94% valuation discount to LFST's 442.5x P/E. On an enterprise value basis, ALKS's 17.3x EV/EBITDA is more attractive than LFST's 42.0x.

MetricBTSG logoBTSGBrightSpring Heal…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcLFST logoLFSTLifeStance Health…
Market CapShares × price$10.2B$1712.35T$5.9B$3.4B
Enterprise ValueMkt cap + debt − cash$13.0B$1712.35T$4.9B$3.4B
Trailing P/EPrice ÷ TTM EPS60.85x-0.76x24.76x442.50x
Forward P/EPrice ÷ next-FY EPS est.34.00x121.07x
PEG RatioP/E ÷ EPS growth rate1.25x
EV / EBITDAEnterprise value multiple22.68x17.25x41.98x
Price / SalesMarket cap ÷ Revenue0.79x4.00x2.41x
Price / BookPrice ÷ Book value/share6.17x0.66x3.28x2.28x
Price / FCFMarket cap ÷ FCF25.91x12.28x31.20x
Evenly matched — BTSG and DBVT and ALKS each lead in 2 of 6 comparable metrics.

Profitability & Efficiency

ALKS leads this category, winning 7 of 9 comparable metrics.

BTSG delivers a 16.7% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-130 for DBVT. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to BTSG's 1.51x. On the Piotroski fundamental quality scale (0–9), BTSG scores 7/9 vs DBVT's 4/9, reflecting strong financial health.

MetricBTSG logoBTSGBrightSpring Heal…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcLFST logoLFSTLifeStance Health…
ROE (TTM)Return on equity+16.7%-130.2%+8.8%+1.6%
ROA (TTM)Return on assets+5.0%-89.0%+5.4%+1.1%
ROICReturn on invested capital+6.7%+18.9%+1.2%
ROCEReturn on capital employed+9.0%-145.7%+14.2%+1.3%
Piotroski ScoreFundamental quality 0–97477
Debt / EquityFinancial leverage1.51x0.13x0.04x0.13x
Net DebtTotal debt minus cash$2.8B-$172M-$1.0B-$55M
Cash & Equiv.Liquid assets$88M$194M$1.1B$249M
Total DebtShort + long-term debt$2.8B$22M$70M$194M
Interest CoverageEBIT ÷ Interest expense2.13x-189.82x32.30x3.30x
ALKS leads this category, winning 7 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

BTSG leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in BTSG five years ago would be worth $48,127 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, BTSG leads with a +129.8% total return vs ALKS's +16.5%. The 3-year compound annual growth rate (CAGR) favors BTSG at 68.8% vs LFST's 1.4% — a key indicator of consistent wealth creation.

MetricBTSG logoBTSGBrightSpring Heal…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcLFST logoLFSTLifeStance Health…
YTD ReturnYear-to-date+37.9%+4.9%+25.3%+27.2%
1-Year ReturnPast 12 months+129.8%+110.4%+16.5%+60.6%
3-Year ReturnCumulative with dividends+381.3%+19.7%+14.5%+4.1%
5-Year ReturnCumulative with dividends+381.3%-69.1%+60.9%-59.6%
10-Year ReturnCumulative with dividends+381.3%-87.0%-11.0%-59.6%
CAGR (3Y)Annualised 3-year return+68.8%+6.2%+4.6%+1.4%
BTSG leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

Evenly matched — ALKS and LFST each lead in 1 of 2 comparable metrics.

ALKS is the less volatile stock with a 1.06 beta — it tends to amplify market swings less than BTSG's 1.46 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LFST currently trades 99.6% from its 52-week high vs DBVT's 76.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricBTSG logoBTSGBrightSpring Heal…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcLFST logoLFSTLifeStance Health…
Beta (5Y)Sensitivity to S&P 5001.46x1.26x1.06x1.20x
52-Week HighHighest price in past year$54.68$26.18$36.60$8.89
52-Week LowLowest price in past year$19.01$7.53$25.17$3.74
% of 52W HighCurrent price vs 52-week peak+96.8%+76.3%+96.7%+99.6%
RSI (14)Momentum oscillator 0–10067.948.160.260.4
Avg Volume (50D)Average daily shares traded3.0M252K2.3M2.9M
Evenly matched — ALKS and LFST each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: BTSG as "Buy", DBVT as "Buy", ALKS as "Buy", LFST as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs -7.9% for BTSG (target: $49).

MetricBTSG logoBTSGBrightSpring Heal…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcLFST logoLFSTLifeStance Health…
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuy
Price TargetConsensus 12-month target$48.75$46.33$44.00$9.30
# AnalystsCovering analysts9152811
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises00
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap+0.4%0.0%+0.5%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

ALKS leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). BTSG leads in 1 (Total Returns). 2 tied.

Best OverallAlkermes plc (ALKS)Leads 2 of 6 categories
Loading custom metrics...

BTSG vs DBVT vs ALKS vs LFST: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is BTSG or DBVT or ALKS or LFST a better buy right now?

For growth investors, BrightSpring Health Services, Inc.

Common Stock (BTSG) is the stronger pick with 14. 6% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Alkermes plc (ALKS) offers the better valuation at 24. 8x trailing P/E, making it the more compelling value choice. Analysts rate BrightSpring Health Services, Inc. Common Stock (BTSG) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — BTSG or DBVT or ALKS or LFST?

On trailing P/E, Alkermes plc (ALKS) is the cheapest at 24.

8x versus LifeStance Health Group, Inc. at 442. 5x. On forward P/E, BrightSpring Health Services, Inc. Common Stock is actually cheaper at 34. 0x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — BTSG or DBVT or ALKS or LFST?

Over the past 5 years, BrightSpring Health Services, Inc.

Common Stock (BTSG) delivered a total return of +381. 3%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: BTSG returned +381. 3% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — BTSG or DBVT or ALKS or LFST?

By beta (market sensitivity over 5 years), Alkermes plc (ALKS) is the lower-risk stock at 1.

06β versus BrightSpring Health Services, Inc. Common Stock's 1. 46β — meaning BTSG is approximately 38% more volatile than ALKS relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 151% for BrightSpring Health Services, Inc. Common Stock — giving it more financial flexibility in a downturn.

05

Which is growing faster — BTSG or DBVT or ALKS or LFST?

By revenue growth (latest reported year), BrightSpring Health Services, Inc.

Common Stock (BTSG) is pulling ahead at 14. 6% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: BrightSpring Health Services, Inc. Common Stock grew EPS 1029% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, BTSG leads at 18. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — BTSG or DBVT or ALKS or LFST?

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is BTSG or DBVT or ALKS or LFST more undervalued right now?

On forward earnings alone, BrightSpring Health Services, Inc.

Common Stock (BTSG) trades at 34. 0x forward P/E versus 121. 1x for LifeStance Health Group, Inc. — 87. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.

08

Which pays a better dividend — BTSG or DBVT or ALKS or LFST?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

09

Is BTSG or DBVT or ALKS or LFST better for a retirement portfolio?

For long-horizon retirement investors, Alkermes plc (ALKS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

06)). Both have compounded well over 10 years (ALKS: -11. 0%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between BTSG and DBVT and ALKS and LFST?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

BTSG

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 12%
Run This Screen
Stocks Like

DBVT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

ALKS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 5%
Run This Screen
Stocks Like

LFST

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 10%
  • Gross Margin > 12%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.